Deceased Florida eaglets test positive for H5N1 bird flu
TAMPA, Fla. (WFLA) — A pair of eaglets that recently died in Florida tested positive for the bird flu, according to researchers.
Eaglets E24 & E25, which were featured on Dick Pritchett Real Estate's Southwest Florida Eagle Cam, both died within a day of each other.
Florida Attorney General reduces pool contractor judgment from $1.9 million to $60 grand
According to the Eagle Cam, E24 had seizures for a few minutes before it suddenly died Monday. While E25 appeared healthy when researchers came to remove its sibling's remains, the remaining eaglet later had seizures and died Tuesday morning after it fell out of the nest.
'This is uncharted territory for our cameras and viewers,' a social media post said.
In a Thursday press conference, officials from the Clinic for the Rehabilitation of Wildlife, also known as CROW, said a necropsy revealed that both eaglets tested positive for highly pathogenic avian influenza, also known as HPAI or bird flu.
While bird flu is typically associated with poultry species, wild birds are highly vulnerable to bird flu.
'The current strain of avian influenza is a highly pathogenic form of the H5N1 virus, which has caused devastating losses in the birds it affects,' Dr. Jessica Comolli said. 'While some birds, such as waterfowl, can shed the virus while remaining asymptomatic, other species, such as birds of prey, are highly susceptible and can succumb to the disease rapidly, as we unfortunately witnessed with the eaglets in this nest.'
Comolli said HPAI can be spread through feces or infected objects, and it appears that the eaglets contracted the disease by eating an infected bird.
'We know that these results are worrisome for all of you and are understandably concerned for the parents,' Comolli said.
The symptoms of HPAI in bird species are typically weakness, difficulty breathing, lack of appetite, an inability to fly or stand, and neurological symptoms like tremors and seizures.
Currently, CROW does not have permission to capture the parents, M15 or F23, for observation due to the danger it would pose to the animals while they are still flying.
'Yesterday they were seen many feet in the air,' Comolli said.
If either of the parents show signs of bird flu infection, CROW asked that you call them at 239-322-5068 or the Florida Fish and Wildlife Conservation Commission at 888-404-3922.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
7 hours ago
- CNBC
FDA approves Moderna's new lower-dose Covid-19 vaccine
The U.S. approved a new Covid-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current Covid-19 vaccine, Spikevax — by refining its immune target. The approval "adds an important new tool to help protect people at high risk of severe disease from Covid-19," Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another Covid-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled Covid-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.

2 days ago
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Chicago Tribune
2 days ago
- Chicago Tribune
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.